BDBM513675 US11091495, Example 36::US11220509, Example 36::US11485738, Example 36
SMILES CN(C)C(=O)c1ccc(cc1F)-c1cnc(NCc2c3CCOc3ccc2F)n2cc(nc12)C#N
InChI Key InChIKey=ZDIVVSQBMFUVPR-UHFFFAOYSA-N
Data 5 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 4 hits for monomerid = 513675
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair